Structural Heart

This structural heart channel includings content related to heart valve repair and replacement, left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and occlusion of ASDs, VSDs and PFOs.

FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019

April 18, 2019 — The U.S. Food and Drug Administration published a draft guidance titled, “...

Videos | Cardiovascular Business | April 16, 2019

A discussion with Ruth Fisher, MBA, vice president of the...

Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators

Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions...

This shows the TEE ultrasound imaging used to guide MitraClip procedures to treat functional mitral regurgitation.
360 Photos | 360 View Photos | April 12, 2019

This 360 degree view shows staff at the...

Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor

April 8, 2019 — Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a...

 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019

April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut...

Essential Medical Inc. received U.S. Food and Drug Administration (FDA) clearance for its large bore Manta Vascular Closure Device. It is designed to close large puncture sites in the femoral artery from larger sized transcatheter devices, including the Impella heart pump, endovascular stent grafts and transcatheter valves.
Technology | Vascular Closure Devices | April 03, 2019

April 3, 2019 — Essential Medical Inc. received U.S. Food and Drug Administration (FDA) clearance for its large bore...

All major vendors offering advanced visualization software now offer structural heart planning. This is an example of GE Healthcare's Valve Assist software being used to determine the best location of a transseptal puncture to deliver a left atrial appendage (LAA) occluder.

All major vendors offering advanced visualization software now offer structural heart planning. This is an example of GE Healthcare's Valve Assist software being used to determine the best location of a transseptal puncture to deliver a left atrial appendage (LAA) occluder. 

Feature | Structural Heart | March 28, 2019 | Jeff Zagoudis

Structural heart interventions represent one of the fastest growing segments of cardiology, as the number of devices...

SCAI Offers Recommendations for Safe Use of PFO Closure Technologies. SCAI said completion of the randomized trials demonstrating the superiority of PFO closure and medical therapy over medical therapy alone
News | Structural Heart Occluders | March 27, 2019

March 27. 2019 — A newly released expert consensus statement provides recommendations for the safe and effective...

TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019

March 22, 2019 — Among patients with severe symptomatic aortic stenosis at low surgical risk,...

Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019

March 20, 2019 — Cook Medical is recalling one lot of its...

Overlay Init